Hexamethylmelamine chemotherapy persistent recurrent epithelial ovarian cancer purpose study activity toxicity hexamethylmelamine chemotherapy patients persistent recurrent epithelial ovarian cancer Forty-nine women hexamethylmelamine mg/day days intervals patients chemotherapy regimen cisplatin patients measurable disease complete partial responses objective response rate mean progression-free interval responders months months nonresponders patients nonmeasurable disease Thirteen patients alive clinical evidence disease patients therapy toxic reactions Hexamethylmelamine well-tolerated drug activity ovarian cancer cisplatin 